The arrival of the Retatru vial represents a significant shift in the field to metabolic management . This groundbreaking medication combines dual mechanisms – stimulation of the GLP-1 target and blocking of the DPP-4 enzyme – suggesting a distinctive method for tackling obesity . Early clinical